170 related articles for article (PubMed ID: 20951769)
1. NFκB/p53 crosstalk-a promising new therapeutic target.
Schneider G; Krämer OH
Biochim Biophys Acta; 2011 Jan; 1815(1):90-103. PubMed ID: 20951769
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile in a glioma cell line resistant to cell death induced by the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53--the role of NFkappaB.
Seznec J; Weit S; Naumann U
Carcinogenesis; 2010 Mar; 31(3):411-8. PubMed ID: 20015865
[TBL] [Abstract][Full Text] [Related]
3. Role of NF-kappaB in p53-mediated programmed cell death.
Ryan KM; Ernst MK; Rice NR; Vousden KH
Nature; 2000 Apr; 404(6780):892-7. PubMed ID: 10786798
[TBL] [Abstract][Full Text] [Related]
4. Analysis of p53 and NF-κB signaling in modulating the cardiomyocyte fate during hypertrophy.
Chatterjee A; Mir SA; Dutta D; Mitra A; Pathak K; Sarkar S
J Cell Physiol; 2011 Oct; 226(10):2543-54. PubMed ID: 21792911
[TBL] [Abstract][Full Text] [Related]
5. Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling.
Kasinski AL; Slack FJ
Curr Opin Mol Ther; 2010 Apr; 12(2):147-57. PubMed ID: 20373258
[TBL] [Abstract][Full Text] [Related]
6. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF.
Huerta S; Heinzerling JH; Anguiano-Hernandez YM; Huerta-Yepez S; Lin J; Chen D; Bonavida B; Livingston EH
J Surg Res; 2007 Sep; 142(1):184-94. PubMed ID: 17603079
[TBL] [Abstract][Full Text] [Related]
7. Wip1-dependent signaling pathways in health and diseases.
Zhu YH; Bulavin DV
Prog Mol Biol Transl Sci; 2012; 106():307-25. PubMed ID: 22340722
[TBL] [Abstract][Full Text] [Related]
8. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.
Hastak K; Gupta S; Ahmad N; Agarwal MK; Agarwal ML; Mukhtar H
Oncogene; 2003 Jul; 22(31):4851-9. PubMed ID: 12894226
[TBL] [Abstract][Full Text] [Related]
9. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy.
Wu JT; Kral JG
J Surg Res; 2005 Jan; 123(1):158-69. PubMed ID: 15652965
[TBL] [Abstract][Full Text] [Related]
10. [Specificity and selectivity of the NFkappaB response].
Czyz M
Postepy Biochem; 2005; 51(1):60-8. PubMed ID: 16209343
[TBL] [Abstract][Full Text] [Related]
11. Nuclear translocation during the cross-talk between cellular stress, cell cycle and anticancer agents.
Tiligada E
Curr Med Chem; 2006; 13(11):1317-20. PubMed ID: 16712472
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between p53 and nuclear factor-B systems: pro- and anti-apoptotic functions of NF-B.
Puszynski K; Bertolusso R; Lipniacki T
IET Syst Biol; 2009 Sep; 3(5):356-67. PubMed ID: 21028926
[TBL] [Abstract][Full Text] [Related]
13. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells.
Bartke T; Siegmund D; Peters N; Reichwein M; Henkler F; Scheurich P; Wajant H
Oncogene; 2001 Feb; 20(5):571-80. PubMed ID: 11313989
[TBL] [Abstract][Full Text] [Related]
14. NFkappaB-dependent chemoresistance in solid tumors.
Arlt A; Schäfer H
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):336-47. PubMed ID: 12467302
[TBL] [Abstract][Full Text] [Related]
15. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy.
Shen HM; Tergaonkar V
Apoptosis; 2009 Apr; 14(4):348-63. PubMed ID: 19212815
[TBL] [Abstract][Full Text] [Related]
16. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling.
Ros JE; Schuetz JD; Geuken M; Streetz K; Moshage H; Kuipers F; Manns MP; Jansen PL; Trautwein C; Müller M
Hepatology; 2001 Jun; 33(6):1425-31. PubMed ID: 11391531
[TBL] [Abstract][Full Text] [Related]
17. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.
Dey A; Tergaonkar V; Lane DP
Nat Rev Drug Discov; 2008 Dec; 7(12):1031-40. PubMed ID: 19043452
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB and IKK as therapeutic targets in cancer.
Kim HJ; Hawke N; Baldwin AS
Cell Death Differ; 2006 May; 13(5):738-47. PubMed ID: 16485028
[TBL] [Abstract][Full Text] [Related]
19. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells.
Zhao J; Lu Y; Shen HM
Cancer Lett; 2012 Jan; 314(1):8-23. PubMed ID: 22030255
[TBL] [Abstract][Full Text] [Related]
20. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
